A Study to Investigate Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Immunogenicity of RO7669330 in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
Public ClinicalTrials.gov record NCT06961370. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase I, Multi-center, Multi-part Study to Investigate Safety, Tolerability, PK, PD, and Immunogenicity of RO7669330 Intravitreal Injections in Participants With GA Secondary to AMD: Part 1A: Open-label, MAD; Part 1B: Randomized PD Pilot; Part 2: Masked, Randomized, Active-comparator-controlled
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The main purpose of this study is to assess the ocular and systemic safety and tolerability of RO7669330 in participants with GA secondary to AMD in at least one eye in Part 1, or both eyes in Part 2, after multiple unilateral intravitreal (IVT) doses.
Study identification
- NCT ID
- NCT06961370
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 27 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 55 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 15, 2025
- Primary completion
- Feb 2, 2026
- Completion
- Mar 2, 2026
- Last update posted
- Aug 9, 2026
2025 – 2026
United States locations
- U.S. sites
- 17
- U.S. states
- 10
- U.S. cities
- 17
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Associated Retina Consultants - Phoenix - DocTrials - PPDS | Phoenix | Arizona | 85020-5505 | — |
| Barnet Dulaney Perkins Eye Center | Sun City | Arizona | 85351 | — |
| Retina-Vitreous Associates Medical Group | Beverly Hills | California | 90211 | — |
| Global Research Management | Glendale | California | 91204 | — |
| Retinal Consultants Medical Group Inc - Parkcenter Drive | Sacramento | California | 95825 | — |
| Southeast Retina Center | Augusta | Georgia | 30909 | — |
| Cumberland Valley Retina Consultants PC | Hagerstown | Maryland | 21740 | — |
| Deep Blue Retina Clinical Research | Southaven | Mississippi | 38671 | — |
| The Retina Institute | St Louis | Missouri | 63128 | — |
| Retina Northwest | Portland | Oregon | 97221 | — |
| Erie Retina Research | Erie | Pennsylvania | 16505 | — |
| Charles Retina Institute | Germantown | Tennessee | 38138 | — |
| Tennessee Retina PC | Nashville | Tennessee | 37203 | — |
| Austin Clinical Research, LLC | Austin | Texas | 78750 | — |
| Texas Retina Associates | Dallas | Texas | 75231 | — |
| Retina Consultants of Texas Westover Hills Retina Center | San Antonio | Texas | 78251 | — |
| Retina Consultants of Texas - (The Woodlands) | The Woodlands | Texas | 77384 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06961370, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 9, 2026 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06961370 live on ClinicalTrials.gov.